EA200900646A1 - Способ получения твердой фармацевтической композиции, содержащей валсартан - Google Patents

Способ получения твердой фармацевтической композиции, содержащей валсартан

Info

Publication number
EA200900646A1
EA200900646A1 EA200900646A EA200900646A EA200900646A1 EA 200900646 A1 EA200900646 A1 EA 200900646A1 EA 200900646 A EA200900646 A EA 200900646A EA 200900646 A EA200900646 A EA 200900646A EA 200900646 A1 EA200900646 A1 EA 200900646A1
Authority
EA
Eurasian Patent Office
Prior art keywords
valsartan
particles
pharmaceutical composition
composition containing
obtaining
Prior art date
Application number
EA200900646A
Other languages
English (en)
Other versions
EA015108B1 (ru
Inventor
Мига Врбинц
Яника Сланц Вовк
Мария Рангус
Силво Зупанчич
Франци Бевец
Лидия Черноша
Original Assignee
Крка, Д.Д. Ново Место
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35966966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200900646(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP04030782A external-priority patent/EP1674080A1/en
Application filed by Крка, Д.Д. Ново Место filed Critical Крка, Д.Д. Ново Место
Publication of EA200900646A1 publication Critical patent/EA200900646A1/ru
Publication of EA015108B1 publication Critical patent/EA015108B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Данное изобретение относится к способу получения твердой фармацевтической композиции, содержащей частицы валсартана, где Dуказанных частиц валсартана составляет 150 мкм или менее, и где частицы валсартана имеют максимальный диаметр не более 1100 мкм, как определено с помощью электронной микроскопии, который включает следующие стадии: получение частиц валсартана, имеющих максимальный диаметр 1100 мкм, - грануляцию смеси эксципиентов с использованием воды или водной дисперсии в качестве грануляционной жидкости с получением гранулята, добавление частиц валсартана и дополнительных эксципиентов к указанному грануляту с получением смеси для прессования, прессование этой смеси для прессования в желаемую форму, возможно, нанесение покрытия.
EA200900646A 2004-12-24 2005-12-23 Способ получения твердой фармацевтической композиции, содержащей валсартан EA015108B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04030782A EP1674080A1 (en) 2004-12-24 2004-12-24 Solid pharmaceutical composition comprising valsartan
EP05004433 2005-03-01

Publications (2)

Publication Number Publication Date
EA200900646A1 true EA200900646A1 (ru) 2009-10-30
EA015108B1 EA015108B1 (ru) 2011-06-30

Family

ID=35966966

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200701107A EA012392B1 (ru) 2004-12-24 2005-12-23 Твердая фармацевтическая композиция, содержащая валсартан
EA200900646A EA015108B1 (ru) 2004-12-24 2005-12-23 Способ получения твердой фармацевтической композиции, содержащей валсартан

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200701107A EA012392B1 (ru) 2004-12-24 2005-12-23 Твердая фармацевтическая композиция, содержащая валсартан

Country Status (16)

Country Link
US (1) US20080102120A1 (ru)
EP (2) EP2033629B1 (ru)
CN (1) CN101087589B (ru)
AU (1) AU2005318365B2 (ru)
CA (1) CA2592091A1 (ru)
DK (1) DK2033629T3 (ru)
EA (2) EA012392B1 (ru)
ES (1) ES2397552T3 (ru)
HR (1) HRP20130033T1 (ru)
ME (1) ME01453B (ru)
NO (1) NO20073889L (ru)
PL (1) PL2033629T3 (ru)
PT (1) PT2033629E (ru)
RS (1) RS52607B (ru)
SI (1) SI2033629T1 (ru)
WO (1) WO2006066961A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2697660C2 (ru) * 2015-02-05 2019-08-16 Борюн Фармасьютикал Ко., Лтд. Таблетка и способ ее получения

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1897537A1 (en) * 2006-09-04 2008-03-12 Novartis AG Composition comprising an angiotensin II receptor antagonist
PE20081364A1 (es) * 2006-09-04 2008-12-04 Novartis Ag Composicion farmaceutica que comprende valsartan
US20080152717A1 (en) * 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof
TR200703568A1 (tr) * 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
GB0715628D0 (en) * 2007-08-10 2007-09-19 Generics Uk Ltd Solid valsartan composition
WO2009113091A2 (en) * 2008-01-24 2009-09-17 Usv Limited Pharmaceutical compositions comprising valsartan
EP2405899A2 (en) * 2009-03-11 2012-01-18 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Valsartan formulations
SI2536396T1 (sl) 2010-02-16 2017-01-31 KRKA, tovarna zdravil, d.d.,Novo mesto Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan
CN102119912A (zh) * 2011-01-25 2011-07-13 南京白敬宇制药有限责任公司 一种非水溶性药物缓释制剂的制备方法
CN102204907A (zh) * 2011-03-31 2011-10-05 北京赛科药业有限责任公司 一种含缬沙坦的药物组合物及其制备方法
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
CN103599084B (zh) * 2013-11-22 2018-10-30 威海迪素制药有限公司 一种降压组合物
CN104887640B (zh) * 2015-06-30 2017-12-19 昆明医科大学 一种含有缬沙坦的固体药物组合物
US20210267908A1 (en) * 2020-03-02 2021-09-02 Mankind Pharma Ltd. Pharmaceutical compositions of rivaroxaban
CN112098408B (zh) * 2020-09-14 2022-12-09 湖北亿纬动力有限公司 一种羧甲基纤维素钠溶解效果的检测方法及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59107440D1 (de) * 1990-02-19 1996-04-04 Ciba Geigy Ag Acylverbindungen
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
TR200805275T2 (tr) 1998-12-23 2008-09-22 Novartis Ag AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6211217B1 (en) * 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
JP2003530343A (ja) * 2000-04-12 2003-10-14 ノバルティス アクチエンゲゼルシャフト アルドステロンシンターゼインヒビター単体またはａｔ１−レセプターアンタゴニストとの組み合わせの新規医薬使用
US6499984B1 (en) 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
CA2411882C (en) 2000-06-22 2011-09-06 Novartis Ag Solid valsartan pharmaceutical compositions
PE20020613A1 (es) * 2000-07-19 2002-08-07 Novartis Ag Sales de (s)-n-(1-carboxi-2-metil-prop-1-il)-n-pentanoil-n-[2'-(1h-tetrazol-5-il)-bifenil-4-ilmetil]-amina como antagonista del receptor at1
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
NZ533968A (en) * 2002-01-17 2006-10-27 Novartis Ag Pharmaceutical compositions comprising valsartan and nep inhibitors
AU2003294883A1 (en) 2002-12-18 2004-07-09 Novartis Ag Combinations of valsartan with cox-2 inhibitors
DE602004013405T2 (de) 2003-03-17 2009-05-07 Teva Pharmaceutical Industries Ltd. Polymorphe formen von valsartan
WO2004094391A2 (en) 2003-04-21 2004-11-04 Teva Pharmaceutical Industries Ltd. Process for the preparation of valsartan and intermediates thereof
US7378531B2 (en) * 2003-04-21 2008-05-27 Teva Pharmaceutical Industries Ltd Process for the preparation of valsartan
US7915247B1 (en) * 2006-08-21 2011-03-29 Mutual Pharmaceutical Company, Inc. Methods of use of fenofibric acid

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2697660C2 (ru) * 2015-02-05 2019-08-16 Борюн Фармасьютикал Ко., Лтд. Таблетка и способ ее получения
US10420728B2 (en) 2015-02-05 2019-09-24 Boryung Pharmaceutical Co., Ltd. Tablet and method of preparing the same

Also Published As

Publication number Publication date
RS52607B (en) 2013-04-30
AU2005318365A1 (en) 2006-06-29
CN101087589B (zh) 2013-01-30
EP2033629B1 (en) 2012-11-14
CA2592091A1 (en) 2006-06-29
EP2033629A1 (en) 2009-03-11
WO2006066961A1 (en) 2006-06-29
HRP20130033T1 (hr) 2013-02-28
EA012392B1 (ru) 2009-10-30
US20080102120A1 (en) 2008-05-01
PT2033629E (pt) 2013-01-24
ME01453B (me) 2014-04-20
CN101087589A (zh) 2007-12-12
ES2397552T3 (es) 2013-03-07
PL2033629T3 (pl) 2013-04-30
EA015108B1 (ru) 2011-06-30
EP1833464A1 (en) 2007-09-19
EA200701107A1 (ru) 2008-04-28
AU2005318365B2 (en) 2011-02-03
DK2033629T3 (da) 2013-02-04
NO20073889L (no) 2007-09-24
SI2033629T1 (sl) 2013-01-31

Similar Documents

Publication Publication Date Title
EA200900646A1 (ru) Способ получения твердой фармацевтической композиции, содержащей валсартан
ATE516796T1 (de) Granulat mit einem pharmazeutischen wirkstoff und einem emulgator und herstellungsverfahren dafür
EP1677159A3 (en) Toner, method for its production and image forming method
EA200702554A1 (ru) Способ получения эпоксида из полигидроксилированного алифатического углеводорода и агента хлорирования
ES2194579B1 (es) Metodo de produccion de fibra que tiene polvo mineral funcional y fibra producida a partir del mismo.
BR0206164A (pt) Partìculas cristalinas de oxalato de escitalopram, método para a produção de partìculas cristalinas de oxalato de escitalopram, e, forma de dosagem unitária sólida
PL1865786T3 (pl) Sposób wytwarzania nadającej się do smarowania dyspersji
RU2006116570A (ru) Ускоритель схватывания цемента
EA200970942A1 (ru) Экстракт пажитника сенного (trigonella foenum-graecum)
EA200801468A1 (ru) Препараты ганаксолона и способы их получения и применения
EA200701653A1 (ru) Быстрый способ влажного формирования массы для получения содержащих кальций композиций
EA201270657A1 (ru) Поливинилпирролидон для стабилизации твердой дисперсии некристаллической формы ротиготина
BR0211705A (pt) Processo para a preparação de uma dispersão estável de partìculas sólidas em um meio aquoso, dispersão estável aquosa, partìcula sólida, composição farmacêutica, método para a inibição do amadurecimento de ostwald em uma dispersão de partìculas sólidas substancialmente insolúveis em água em um meio aquoso, e, uso de um inibidor
CA2557107A1 (en) Process for production of ionically crosslinked polysaccharide microspheres
DE602005018928D1 (de) Ahren zur herstellung der granulate
MX2009005581A (es) Particulas estables de lactido.
EA200400487A1 (ru) Фармацевтическая композиция длительного высвобождения, содержащая метформин
UA97942C2 (ru) Твердая фармацевтическая композиция, содержащая валсартан
EA201001537A1 (ru) Гранулированная агрохимическая композиция и способы её получения
TW200508264A (en) Method for deashing by a polymer and method for producing said polymer
EA201071024A1 (ru) Смесь для получения быстро разрушающихся таблеток
ATE460979T1 (de) Verfahren zur herstellung von nanoskaligen pulvern
EA200601373A1 (ru) Нитрат бутоконазола высокой степени чистоты с частицами заданного размера и способ его получения
WO2011087705A3 (en) Fine particle croscarmellose and uses thereof
ATE503005T1 (de) Knochenbildungszusammensetzung aus osteoblastengemisch und biomatrix und herstellungsverfahren dafür

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU